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Best practice strategies regarding primary antifungal prophy-
laxis in leukemiapatients and inhematopoietic stemcell transplant
recipients continue to evolve. For this prophylaxis to be beneﬁ-
cial and cost-effective, the risk of a life-threatening invasive fungal
infection (IFI) should outweigh the risks of toxic effects and drug
interactions introduced by the antifungal agent used. Furthermore,
the improved survival of such patients with IFIs creates pressing
issues regarding optimization of secondary antifungal prophy-
laxis. Not all patients with hematologic cancer recipients have the
same risk of IFIs. Well tolerated and pharmacokinetically reliable,
broad-spectrum antifungals, especially azoles, have the potential
for reducing IFI-associated mortality in these patients. Further
reﬁnement of risk stratiﬁcation and risk/beneﬁt analysis (includ-
ing pharmacoeconomic analysis) is needed. Stratiﬁcation of IFI risk
could be further sharpened based on emerging genetic, metabolic
risk factors. Despite robust data from randomized prospective
studies, personalized decisions and reliance on institution-speciﬁc
epidemiologic data are still expected to be a major part of “art and
science” of prophylaxis for fungal infections in severely immuno-
suppressed hosts.
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Implication of current resistance trends on
community-acquired respiratory tract infection
(CA-RTI) management
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As the prevalence of antibiotic-resistant Streptococcus pneumo-
niae, includingmultidrug-resistant strains is variableworld-wide1,
ﬁrst-line therapy with beta-lactams, macrolides, and increasingly
quinolones, in some regions has become limited in the treatment
of respiratory tract infections (RTIs). Therefore, one of the impor-
tant principles for appropriate antibiotic prescribing and effective
outcomes in this clinical setting is to recognise local resistance
prevalence.2 The aim of surveillance is both to guide empirical
antibiotic use and to improve the quality of empirical antimicro-
bial treatment in the community (as well as the hospital setting).3
In addition, introduction of pneumococcal vaccines may alter the
predominant serotypes with potentially unique antimicrobial sus-
ceptibility patterns.
There have been a number of international surveillance sys-
tems established including the ALEXANDER PROJECT, PROTEKT,
LIBRA, SENTRY, ANSORP4 and SIREVA.5 Survey Of Antibiotic Resis-
tance (SOAR)6 is the latest of the international surveillance studies
that offer standardised, internationally recognised methods that
provide quantitative data (minimum inhibitory concentrations
[MIC]) that may show slight shifts in resistance - as seen in pub-
lished SOAR data.6 These ‘shifts’ in antibioticMICs can be overcome
by extending the time above MIC (T >MIC) for which amoxicillin,
for example, is present in serum.7
In addition to MIC shifts, an increase in the prevalence of
Haemophilus inﬂuenzaehasbeenobserved inupperRTIs subsequent
towide-scale use of pneumococcal conjugate vaccines in children.8
This phenomenon, as well as an increase in beta-lactamase pro-
duction amongst H.inﬂuenzae in certain parts of the world, has
necessitated the ﬁrst line empirical use of amoxiciilin-clavulanate
as opposed to amoxicillin alone.9 Continuous surveillance through
standardised systems is therefore crucial to guide clinicians in
rational antibiotic prescribing for community acquired RTIs.
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What is ‘judicious use of antibiotics’ and is it
achievable in children?
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Judicious use of antibiotics is promoted largely because of the
threat of antibiotic-resistant pathogens. The most common rea-
sons for antibiotic prescriptions in all ages are respiratory tract
infections (RTIs). The most common patients to receive antibiotics
are infants and young children, and among these, the commonest
diagnosis for which antibiotics are prescribed is otitis media.
Antibiotic resistance in the community is spread through selec-
tion of antibiotic-resistant respiratory ﬂora submitted to antibiotic
pressure during treatment of various acute diseases. Not all antibi-
otics are equal in their effect on promotion of antibiotic resistant
organisms. Using the pneumococcus paradigm, azithromycin is
the antibiotic with the highest promotion of resistance, due to
its long half life and low extra-cellular concentration; followed by
oral cephalosporins. Traditionally, “judicious use of antibiotics” is
translated by most clinicians as “reducing antibiotic use”. How-
ever judicious use means much more than that. There is a need
to consider all the following to successfully execute a judicious use
of antibiotics (as summarized by Ball et al, Journal of Antimicrobial
Chemotherapy 2002;49:31-40): 1) Treatment of bacterial infections
only; 2) optimize treatment by diagnosis and severity assessment;
3) maximize bacterial eradication; 4) recognize local resistance
prevalence; 5) utilize pharmacokinetics/pharmacodynamics for
